Healthy Control Human iPSC Line, Female, SCTi003-A

Human pluripotent stem cell line, frozen

Additional license fees may apply. Select the Request Pricing button to submit your request and a representative will contact you with a quote.

Healthy Control Human iPSC Line, Female, SCTi003-A

Human pluripotent stem cell line, frozen

Catalog #
200-0511_C
Human pluripotent stem cell line, frozen
Request Pricing

Product Advantages


  • Meet regulatory requirements for academic and/or commercial purposes with ethically sourced human iPSCs collected using IRB protocols.

  • Trust in extensive quality control that meets or exceeds industry standards at every step of the manufacturing process (ISCBI, 2009)

  • Enhance research transparency, and ethical and biological conformity, by using a cell line certified by hPSCreg®

  • Confidently integrate human iPSCs into your workflow with a cell line that is compatible with TeSR™ media for maintenance and STEMdiff™ for differentiation

What's Included

  • Healthy Control Human iPSC Line, Female, SCTi003-A (Catalog #200-0511)
Additional license fees may apply. Select the Request Pricing button to submit your request and a representative will contact you with a quote.

Overview

Start your research confidently with a reliable source of high-quality induced pluripotent stem cells (iPSCs) from the SCTi003-A cell line. SCTi003-A is derived from healthy female donor peripheral blood mononuclear cells (PBMCs), making it suitable for various applications, such as for use as an unaffected control, gene editing, or downstream differentiation to lineage-specific cell types and organoids.

To ensure optimal product performance and reproducibility, SCTi003-A is manufactured using extensive quality control procedures in a culture system consisting of mTeSR™ Plus, Corning® Matrigel® hESC-Qualified Matrix, and ReLeSR™. SCTi003-A is karyotypically stable, demonstrates trilineage differentiation potential, expresses undifferentiated cell markers, and was reprogrammed using a non-integrating reprogramming technology. Registration with hPSCreg® ensures ethical and biological conformity based on community standards.

Validated for expansion in the PBS-MINI Bioreactor, the SCTi003-A cell line provides a pathway for efficient scale-up of your cultures. It has also been validated with STEMdiff™ kits across multiple lineages and tissue types in both 2D and organoid models (Figures 6-11). Browse TeSR™ and STEMdiff™ cell culture media products to establish a complete workflow for your cell culture system.

This research-use-only (RUO) product has been consented for both academic and commercial use. Blood samples are ethically sourced using Institutional Review Board (IRB) or other regulatory authority-approved consent forms and protocols. For donor details and cell quality characterization of the source cell banks refer to the data figures on this page. SCTi003-A is derived from an αβ T cell and has undergone VDJ sequence rearrangement. For additional details, refer to the lot-specific Certificate of Analysis and Frequently Asked Questions About Induced Pluripotent Stem Cell Lines.

The whole exome sequencing data is available upon request. Please contact us for pricing.
Contains
CryoStor® CS10
Subtype
Frozen
Cell Type
Pluripotent Stem Cells
Species
Human
Cell and Tissue Source
Peripheral Blood
Brand
STEMdiff, TeSR
Area of Interest
Cell Line Development, Disease Modeling, Drug Discovery and Toxicity Testing, Infectious Diseases, Neuroscience, Organoids, Stem Cell Biology
Donor Status
Normal
Purity
≥ 80% TRA-1-60+ and OCT4+ by flow cytometry

Data Figures

Data table presenting donor characteristics that apply to iPSC line SCTi003-A

Figure 1. iPSC Line SCTi003-A Is Derived from a Healthy Female Donor

Demographic, health, and genetic characteristics of the SCTi003-A donor are compiled based on self-reported information and whole-exome sequencing. Sex was determined by karyotype. Ancestry was calculated by EthSEQ analysis from whole-exome sequencing data. HLA haplotype was determined by next-generation sequencing, sequence-base typing, and sequence-specific oligonucleotide probes as needed to obtain the required resolution. Other genetic variants were determined from whole-exome sequencing using ClinVar analysis. Blood type (ABO/Rh blood group) was determined by next-generation sequencing. Height, weight, and BMI were calculated at the donation facility. iPSC = induced pluripotent stem cell.

Brightfield images of increasing magnification show typical healthy iPSC morphology

Figure 2. SCTi003-A Human Pluripotent Stem Cells Demonstrate High-Quality Morphology in Routine Culture

Cryopreserved cells from line SCTi003-A were thawed and maintained in mTeSR™ Plus on Corning® Matrigel® Matrix. (A) The resulting iPSC colonies have densely packed cells and show multi-layering when ready to be passaged. (B,C) Cells retain prominent nucleoli and high nuclear-to-cytoplasmic ratios. iPSC = induced pluripotent stem cell.

Chromosomes arranged in a normal karyotype and a cell image showing 2 fluorescent in situ hybridization probes

Figure 3. SCTi003-A Human Pluripotent Stem Cells Maintain a Normal Karyotype

(A) G-T-L banding for thawed cells at p26 (n = 20) shows a normal karyotype with no evidence of clonal abnormalities at a band resolution of 450 - 550 G-bands per haploid genome. (B) Fluorescent in situ hybridization in a representative p26 iPSC using probes for 20p11 (green) and 20q11.21 (red). 94% of cells examined displayed two sets of two probe signals, indicating no aneusomy of chromosome 20 (n = 200). iPSC = induced pluripotent stem cell.

Data table presenting a list of chromosomal gains and losses determined by SNP microarray

Figure 4. Single Nucleotide Polymorphism Microarray Analysis Characterizes SCTi003-A Copy Number Variants

DNA was extracted from a vial of SCTi003-A from the Master Cell Bank and subject to SNP microarray analysis to identify large-scale copy number variants (CNVs). The cells display two reportable CNVs, defined as those greater than 400kb in size, on chromosome 7 and 14 (rows highlighted in bold font). These losses are located in the TCR regions of the genome and are indicative of VDJ recombination process during T Cell development. chr = chromosome; start cyto = cytogenetic band at the start of the base pair imbalance; end cyto = cytogenetic band at the end of the base pair imbalance; bp = base pairs; SNP = single nucleotide polymorphism; TCR = T Cell Receptor; VDJ = variable, diversity, joining segment.

Bar graph and flow cytometry plot quantification of OCT3/4 and TRA-1-60 gene expression

Figure 5. SCTi003-A iPSCs Express Undifferentiated Cell Markers

Cell line SCTi003-A was characterized using flow cytometry for undifferentiated cell markers OCT3/4 and TRA-1-60. (A) Percentage marker expression was quantified 5 passages after thawing from the Master Cell Bank from analyses of three technical replicates. Representative flow cytometry plots are displayed for (B) TRA-1-60 and (C) OCT3/4. iPSC = induced pluripotent stem cell.

Bar graph quantifying gene expression of 6 trilineage markers by flow cytometry

Figure 6. SCTi003-A Human Pluripotent Stem Cells Demonstrate a High Trilineage Differentiation Capacity

Cells from SCTi003-A were split into 3 groups, differentiated using STEMdiff™ Trilineage Differentiation Kit (#05230), and then subjected to flow cytometry analysis. Two markers for each embryonic germ layer were assessed, and bars present mean marker expression for each group of cells (n = 2 biological replicates). PAX6 and Nestin confirm differentiation to the ectoderm lineage, NCAM and Brachyury (T) to the mesoderm lineage, and CXCR4 and SOX17 to the endoderm lineage.

Confirmation of hematopoietic progenitor cell markers and morphology, and CFU assay results for hematopoietic differentiation of SCTi003-A

Figure 7. SCTi003-A iPSCs Can Form Hematopoietic Progenitor Cells and Have Colony-Forming Potential

STEMdiff™ Hematopoietic Kit (#05310) was used to generate HPCs from the SCTi003-A cell line. (A) Percentages and yields of CD34+CD45+ HPCs per cm2 after differentiation (n = 2 biological replicates). (B) Brightfield image of SCTi003-A-derived HPCs indicates that these cells transitioned through a typical endothelial-to-hematopoietic transition (EHT). The resulting HPCs were then subject to a CFU assay (n = 2) with MethoCult™ SF H4636. (C) After 14 days of incubation, colonies were imaged with STEMvision™ and (D) enumerated from digital images. Both myeloid (black) and erythroid (red) colonies can be formed from this line. iPSCs = induced pluripotent stem cells; HPCs = hematopoietic progenitor cells; CFU = colony-forming unit.

Confirmation of microglia cell markers and brightfield morphology

Figure 8. SCTi003-A Human Pluripotent Stem Cells Can Effectively Differentiate into Microglia

Hematopoietic progenitor cells generated from cell line SCTi003-A using the STEMdiff™ Hematopoietic Kit (#05310) were further differentiated using STEMdiff™ Microglia Differentiation and Maturation Kits (#100-0019, #100-0020). (A) The resulting cells are small with visible processes, are non-adherent on Matrigel®, and exhibit small cytoplasmic-to-nuclear ratios characteristic of microglia. (B) Co-expression of CD45 and CD11b was observed by flow cytometry. (C) The resulting cells are also adherent on poly-D-lysine, and contain < 20% monocyte-like cells (large, with lightly stained cytoplasm; arrow) as assessed by May-Grunwald Giemsa stain at Day 27.

Immunofluorescent images of 2 neural progenitor markers, a mature neuron marker, and a nuclear stain along with their quantification

Figure 9. SCTi003-A Human Pluripotent Stem Cells Can Efficiently Differentiate into Neural Progenitor Cells

NPCs were generated from SCTi003-A iPSCs using STEMdiff™ SMADi Neural Induction Kit (#08581) following the monolayer protocol in the Product Information Sheet, and subsequently cryopreserved. The resulting NPCs were thawed, established in culture, and fixed for immunocytochemistry. The NPCs express neural progenitor markers (A) SOX1 and (B) PAX6 with low expression of (C) class III β-tubulin (TUJ1). (D) In addition, they display the expected small, teardrop-shaped morphology. (E) Marker expression was quantified and found to be greater than 90% for neural progenitor markers and less than 10% for mature neuronal markers. Error bars represent standard deviation (n = 2 biological replicates). NPCs = neural progenitor cells; iPSCs = induced pluripotent stem cells.

Coordinated contraction or beating behavior of cardiomyocytes in a culture dish, and quantification of the beat frequency and duration

Figure 10. SCTi003-A Human Pluripotent Stem Cells Can Successfully Differentiate into Ventricular Cardiomyocytes

Ventricular cardiomyocytes were generated from SCTi003-A iPSCs using STEMdiff™ Ventricular Cardiomyocyte Differentiation Kit (#05010). (A) Monolayer cultures at Day 15 of differentiation show iPSC-derived ventricular cardiomyocytes that exhibit beating behavior. (B) Beating ventricular cardiomyocytes can be replated and maintained in a well of an MEA plate for functional analysis. (C) Of the resulting cells, 89% express cardiomyocyte marker cTnT, as detected by flow cytometry. (D) The iPSC-derived ventricular cardiomyocytes at Day 22 of differentiation beat at ~25 BPM (n = 3 replicates, mean +/-SD plotted) and (E) have a field potential duration of ~500 ms (n = 3 replicates, mean +/-SD plotted), as assessed by MEA. iPSCs = induced pluripotent stem cells; MEA = microelectrode array.

Immunofluorescent images of 2 neuronal markers, an astrocyte marker, and a nuclear stain in a dorsal forebrain organoid at low and high magnification

Figure 11. SCTi003-A Human Pluripotent Stem Cells Can Successfully Differentiate into Neural Organoids

iPSCs from SCTi003-A were differentiated to neural organoids using STEMdiff™ Dorsal Forebrain Organoid Differentiation Kit (#08620). Dorsal forebrain organoids were maintained until Day 105 with STEMdiff™ Neural Organoid Maintenance Kit (#100-0120) before fixing, cryosectioning, and immunofluorescent staining. The resulting organoids were stained for (A) DAPI (blue), (B) MAP2 (magenta), (C) NEUN (yellow), and (D) GFAP (cyan). (E) 4-channel merged image. Panels show cellular-level detail at 63x magnification. Insets show the full cryosection at 10x magnification. iPSCs = induced pluripotent stem cells.

13-day time course brightfield images of iPSCs differentiating into intestinal organoids, changing morphology, and detaching from the culture plate

Figure 12. Human Pluripotent Stem Cells from Line SCTi003-A Can Successfully Differentiate into Intestinal Organoids

(A) SCTi003-A iPSCs were plated down for use with STEMdiff™ Intestinal Organoid Kit (#05140). (B) By Day 3 of the protocol outlined in the Product Information Sheet, the monolayers show more uniformity and display characteristics of patterning to definitive endoderm. (C) After switching to mid-/hindgut medium, 3D structures become visible atop the monolayer culture, and (D) spheroids detach from the mid-/hindgut culture at Day 7 of differentiation. (E) Collections of spheroids can be embedded in Matrigel® domes for subsequent maturation into human intestinal organoids, which (F) expand significantly after just 6 days in matrix. The maturing organoids can be passaged and expanded using STEMdiff™ Intestinal Organoid Growth Medium (#05145). iPSCs = induced pluripotent stem cells.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
200-0511
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (32)

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.